Efficacy Of 100 Mg SC Mepolizumab For Severe Eosinophilic Asthma (SEA) Across Blood Eosinophil Counts: Meta‐Analysis: 305
Abstract
S U N D A Y Jean Bousquet, Jorge F. Maspero, Bradley E. Chipps, MD, Jonathan Corren, J. Mark FitzGerald, Zhen Chen, Yufang Lu, Paul Rowe, Heribert Staudinger, Marcella Ruddy, Neil M. H. Graham, Siddhesh Kamat, Nikhil Amin, Ariel Teper, and Asif Khan; MACVIA-France (contre les maladies chroniques pour un vieillissement actif en France) and Fondation FMC VIA-LR, Montpellier, France, Allergy and Respiratory Research Unit, Fundaci on CIDEA, Buenos Aires, Argentina, Capital Allergy and Respiratory Disease Center, Sacramento, CA, David Geffen School of Medicine at UCLA, Los Angeles, CA, University of British Columbia, Vancouver, Canada, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, Sanofi, Bridgewater, NJ, Sanofi, Chilly-Mazarin, France. RATIONALE: Allergic rhinitis (AR), a common type 2 comorbidity in asthma patients, contributes to increased overall disease burden. Dupilumab, a fully human, VelocImmune -derived anti-interleukin (IL)4Ra mAb that inhibits signaling of IL-4/IL-13, key drivers of type 2 inflammation, is approved for treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis. This analysis of the phase 3 LIBERTY ASTHMA QUEST study (NCT02414854) in uncontrolled, moderate-to-severe asthma patients assessed dupilumab’s effect on the Standardized Rhinoconjunctivitis Quality of Life Questionnaire [RQLQ(S)+12] in patients with self-reported comorbid AR. METHODS: Asthma patients, >_12 years, uncontrolled with medium-tohigh-dose ICS plus <_2…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.